Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA3 | P07451 | 3/20 | 0.36 |
| ▸ | CA6 | P23280 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041668 | 0.87 | NR1H2 (0.48) | GPR119NR1H2NR1H3CA12CA2 | |
| SCHEMBL17242214 | 0.87 | NR1H2 (0.38) | GPR119NR1H2NR1H3PTGS1AKR1C3 | |
| SCHEMBL23727382 | 0.85 | NR1H2 (0.36) | GPR119NR1H2NR1H3PTGS1AKR1C3 | |
| SCHEMBL15878871 | 0.81 | GPR119 (0.37) | GPR119NR1H2 | |
| SCHEMBL22980683 | 0.80 | HDAC8 (0.36) | NR1H2NR1H3PTGS1AKR1C3AKR1C2 | |
| SCHEMBL17965623 | 0.80 | ESR2 (0.46) | NR1H2MEN1KMT2A | |
| SCHEMBL15878939 | 0.79 | CHKA (0.47) | MEN1KMT2AHDAC6KDM4ELMNA | |
| SCHEMBL1394177 | 0.79 | NR1H2 (0.47) | NR1H2NR1H3MEN1KMT2AKDM4E | |
| SCHEMBL2144869 | 0.79 | USP30 (0.40) | NR1H2HDAC1NPC1LMNAMAPT | |
| SCHEMBL2143961 | 0.79 | GABRG2 (0.41) | GPR119NR1H2NR1H3SETD7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12517130-B2 | Isoindoline derivatives which bind to an ATP binding site | Neophore Limited (GB) | 2026-01-06 | — | — | US | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4373819-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021229152-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021148786-A1 | ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE | Neophore Limited (GB) | 2021-07-29 | — | — | WO | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| WO-2018218154-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20160090364-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-31 | — | — | US | disclosed |
| US-9221767-B2 | Substituted phthalazinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140206686-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206686-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | GPR119 1862/4885NR1H2 1671/4885NR1H3 2014/4885 |
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | GPR119 3556/4885NR1H2 4732/4885NR1H3 4783/4885 |
| US-20160090364-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | GPR119 1862/4885NR1H2 1671/4885NR1H3 2014/4885 |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | GPR119 2087/4885NR1H2 2027/4885NR1H3 2514/4885 |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | GPR119 1904/4885NR1H2 90/4885NR1H3 144/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | GPR119 3556/4885NR1H2 4732/4885NR1H3 4783/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | GPR119 3/4885NR1H2 486/4885NR1H3 812/4885 |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GPR119 3/4885NR1H2 486/4885NR1H3 812/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | GPR119 3/4885NR1H2 188/4885NR1H3 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.